Platelet count >= ,/ul
Platelet count >= ,/uL
Platelet count >=,/ul
Platelet count >= ,/ul; for patients with >= % plasma cell involvement of the bone marrow, platelet count >= ,/ul is acceptable
Platelet count >= ,/ul (>= , per mm^) must be met within  days of CD
Platelet count of >= ,/uL
Platelet count > ,/uL
Platelet count >= ,/uL, within  days of registration
Platelet count >= ,/uL
Platelet count ? ,/uL
Platelet count < ,/uL without full-dose anticogulation therapy
Platelet count < ,/uL with ongoing full-dose anticoagulation therapy
Platelet count >=  K/uL within  days prior to start of protocol therapy.
Platelet count > ,/uL
PHASE I: Platelet count >= ,/uL
PHASE IB: Platelet count >= ,/uL
Platelet count of >= ,/uL
Platelet count < ,/uL
Platelet count > ,/ul within four weeks of enrollment
Platelet count >= , K/uL
Platelet count >= ,/?l (except in hepatocellular carcinoma patients with portal hypertension for whom a platelet count > ,/ul is allowed)
Platelet count >= ,/uL
Platelet count >= ,/uL.
TREATMENT WITH SJCAR: Platelet count > ,/uL (can be transfused)
Platelet count < ,/uL
Within  days prior to treatment start: Platelet count >= ,/ul
Platelet count >= ,/uL
Platelet >= ,/uL
Platelet count >= ,/uL
Platelet count >=  x ^/L (>= , /uL)
Platelet count =< , x ^/uL at the screening visit
Platelet count >= , cells/uL
Platelet count >  K/uL
Platelet count >= ,/uL
Platelet count > ,/uL unless disease-related (due to marrow infiltration or splenomegaly)
Platelet count of >= ,/uL
Platelet count >= ,/uL
Platelet count < ,/uL
Platelet count >= ,/uL
Platelet count <  K/uL
Platelet count > ,/uL
Platelet count >= ,/uL
Platelet count >= ,/uL prior to biopsy; platelets >= ,/uL prior to infusion
Platelet count >= ,/uL
Within  days prior to the first study treatment (cycle , day ): Platelet count >= ,/uL; for patients with hematologic malignancies, platelet count >= ,/uL
Platelet count >= ,/uL; for patients with hematologic malignancies, platelet count >= ,/uL
Platelet ? ,/uL
Platelet count ?,/uL
Within  days of registration: Platelet count >= ,/ul
Platelet count >= ,/ul prior to biopsy; platelet count >= ,/ul prior to infusion
Platelet count >= ,/uL
Platelet count >= , cells/uL
Platelet count >= ,/uL
Platelet count of >= ,/uL
Platelet count of >= ,/ul
Platelet count >= ,/uL within  days prior to CD
Platelet count >= ,/uL
Platelet count > K/uL
Platelet count >= , platelets/ul
Platelet count >= ,/uL
Platelet count < ,/uL
Platelet count >= ,/uL
ARM A COHORT : Platelet count >= ,/ul
ARM B COHORT : Platelet count >= ,/ul
ARM B COHORT : Platelet count >= ,/ul
ARM C COHORT : Platelet count >= ,/ul
Platelet count >= ,/uL
Must be met within  days of CD: Platelet count >= ,/ul
Platelet >= ,/uL
Platelet count >= ,/uL
Platelet count >= ,/uL
Platelet count >= ,/uL
Platelet count >= , cells/uL
Platelet count >= ,/ul (phase I only)
Platelet count >= ,/uL
Platelet count >=  x ^ /uL without platelet transfusions
Platelet count >= ,/ul
Platelet count >= ,/ul
Platelet count >=  K/uL (in the expansion cohorts, if thrombocytopenia is due to bone marrow involvement platelet count must be >=  K/uL), without platelet transfusions for  week
Platelet count < ,/ul
Platelet > ,/uL
Platelet count > ,/uL during screening evaluation
Platelet count >= , cells/ul
Within  days prior to the first study treatment (cycle , day ): Platelet count >= ,uL for patients with hematologic malignancies, platelet count >= ,/uL.
Platelet count >/= , platelets/ul prior to initial treatment
Platelet count >= ,/uL
Platelet count >= ,/ul
Platelet count >= ,/uL
Platelet count >= ,/uL
Platelet count >= ,/uL
Platelet count >= ,/uL
Platelet count >= ,/ul
Platelet >= ,/uL
Platelet count >= ,/uL
Platelet count >= ,/uL; for patients with hematologic malignancies, platelet count >= ,/uL
Platelet count >= , cells/uL
Platelet count > ,/ul
Patients must have a platelet count >= ,/uL at the time of the initial evaluation
Platelet count of greater than ,/uL
Platelet count >= ,/uL
Platelet count >= ,/uL
Platelet count >= ,/ul
Platelet count > ,/ul
Platelet count >= ,/UL
Platelet count >= ,/uL
Platelet >= ,/uL
Platelet count >= ,/uL
Platelet count >= ,/uL
Platelet count >= ,ul
Platelet ? , / uL
Platelet count >= ,/uL
Platelet count > ,/uL
Platelet count (untransfused) >= ,/uL
Platelet count > ,/uL
Platelet count >  K/uL
Presence of significant active bleeding or condition requiring maintenance of a platelet count > ,/uL
Platelet count >= ,/uL
Platelet count > ,/uL or > ,/uL if bone marrow (BM) involvement or splenomegaly
Within  days prior to the first study treatment (cycle , day ): Platelet count >= ,/uL; for patients with hematologic malignancies, platelet count >= ,/uL
Platelet count > ,/ul
Platelet count >= ,/uL
Platelet count >=  K/u (in the Phase IIa portion, if thrombocytopenia is due to bone marrow involvement platelet count must be >=  K/uL)
Platelet count >= ,/uL
Platelet count >= , cells/uL
Platelet count >= ,/uL
Platelet count >= ,/ul
Platelet count < ,/uL
The platelet count must be at least ,/uL
Platelet count >=  x ^/uL
Untransfused platelet count >= ,/uL
Platelet count >= ,/uL
Thrombocytopenia (platelet count <  x ^/uL)
Platelet count >= ,/uL
Platelet count of less than ,/uL
Platelet count =< ,/uL
Platelet count >=  K/uL, if thrombocytopenia is due to bone marrow involvement platelet count must be >=  K/uL
Platelet count >= ,/ul
Platelet count >= ,/ul
Platelet count >= ,/ul prior to biopsy; platelets >= ,/ul prior to infusion
Platelet count >= ,/uL
Platelet count >= ,/uL
Platelet count >= ,/ul
Platelet count > ,/ul
Platelet count >= ,/uL
Platelet count of > ,/ul
Platelet count >= ,/ul
Thrombocytopenia (platelet count <  x ^/uL)
Platelet count must be >= ,/uL
Platelet count >= ,/uL
Platelet count >= ,/ul
Platelet count ? ,/uL
Platelet count > ,/ ul 
Platelet count >= ,/uL
Platelet >= ,/uL
Platelet count >= ,/ul
Platelet count >= ,/ul
Platelet >= ,/uL
Platelet count >= ,/uL
(Untransfused) platelet count >= /uL
Untransfused platelet count >= /uL
Platelet count > /uL
Platelet count >= ,/uL
Platelet count >= ,/uL
Platelet count of >= ,/uL
Platelet count < ,/uL
Platelet count >= ,/ul (corrected if needed)
Platelet count >= ,/uL
Platelet count >= ,/uL
Platelet count >= ,/uL
Platelet count > ,/uL
Platelet count > ,/ul
Platelet count: -/uL
Stable platelet count >= ,/mm^ (>=  k/uL)
Platelet count >= ,/ul
Platelet count of =< ,/uL
Existing major organ dysfunction > grade , with the exception of myelosuppression (neutrophil count >= /ul and platelet count >= ,/ul are acceptable) and hearing loss
Platelet count has to be >= ,/uL in patients undergoing biopsy
Platelet count >= ,/uL
Unacceptable hemogram: platelet count < ,/ul
Platelet > ,/uL
Platelet count > /uL